Brought to you by 
BioMarin and Daiichi develop PKU therapeutic Phenoptin
09 Dec 2004
Executive Summary
Daiichi Suntory Pharma and BioMarin Pharmaceutical (therapeutics for serious pediatric diseases) are collaborating to develop Phenoptin (6R-BH4), BioMarin's oral formulation of the naturally occurring enzyme cofactor tetrahydrobiopterin, to treat phenylketonuria (PKU), a genetic disease in evidence within moments after birth.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
BioMarin and Daiichi develop PKU therapeutic Phenoptin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice